share_log

Allarity Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-3i, LP(0%),3i Management LLC(0%), etc.

Allarity Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-3i, LP(0%),3i Management LLC(0%), etc.

Allarity Therapeutics | SC 13G/A：超过5%持股股东披露文件(修正)-3i, LP(0%),3i Management LLC(0%)等
美股SEC公告 ·  2024/11/14 10:28

Moomoo AI 已提取核心信息

Allarity Therapeutics, Inc. has filed an Amendment No. 2 to the Schedule 13G with the U.S. Securities and Exchange Commission (SEC), indicating significant changes in ownership by reporting persons. The amendment, dated September 30, 2024, reflects the aftermath of a 1-for-30 reverse stock split of the company's common stock that occurred on September 9, 2024. The filing was made by three reporting persons: 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, all of whom have ceased to be the beneficial owners of more than five percent of Allarity Therapeutics' outstanding common stock. This amendment serves as an exit filing for each of the reporting persons, marking their departure from a significant ownership position in the company. The principal business address for all reporting persons is listed as 2 Wooster Street, 2nd Floor, New York, NY 10013. The filing emphasizes that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
Allarity Therapeutics, Inc. has filed an Amendment No. 2 to the Schedule 13G with the U.S. Securities and Exchange Commission (SEC), indicating significant changes in ownership by reporting persons. The amendment, dated September 30, 2024, reflects the aftermath of a 1-for-30 reverse stock split of the company's common stock that occurred on September 9, 2024. The filing was made by three reporting persons: 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, all of whom have ceased to be the beneficial owners of more than five percent of Allarity Therapeutics' outstanding common stock. This amendment serves as an exit filing for each of the reporting persons, marking their departure from a significant ownership position in the company. The principal business address for all reporting persons is listed as 2 Wooster Street, 2nd Floor, New York, NY 10013. The filing emphasizes that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
Allarity Therapeutics, Inc. 已向美国证券交易委员会 (SEC) 提交了第 2 号修正案，表明报告人股权发生了重大变化。该修正案的日期为2024年9月30日，反映了2024年9月9日公司普通股进行1比30的反向股票拆分后的结果。该文件由三位报告人提交：3i, LP、3i Management LLC和Maier Joshua Tarlow，他们都不再是Allarity Therapeutics发行在外的普通股的超过五个百分点的实益拥有者。这份修正案作为每位报告人的退出申报，标志着他们退出了公司中一个重要的持股位置。所有报告人的主要商业地址列为纽约市伍斯特街2号2楼，邮政编码10013。该文件强调这些股份不是为了改变或影响发行人控制权而获取的。
Allarity Therapeutics, Inc. 已向美国证券交易委员会 (SEC) 提交了第 2 号修正案，表明报告人股权发生了重大变化。该修正案的日期为2024年9月30日，反映了2024年9月9日公司普通股进行1比30的反向股票拆分后的结果。该文件由三位报告人提交：3i, LP、3i Management LLC和Maier Joshua Tarlow，他们都不再是Allarity Therapeutics发行在外的普通股的超过五个百分点的实益拥有者。这份修正案作为每位报告人的退出申报，标志着他们退出了公司中一个重要的持股位置。所有报告人的主要商业地址列为纽约市伍斯特街2号2楼，邮政编码10013。该文件强调这些股份不是为了改变或影响发行人控制权而获取的。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。